Header Logo

Roumen D Balabanov

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
AddressChicago IL 60612
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Arellano G, Loda E, Chen Y, Neef T, Cogswell AC, Primer G, Joy G, Kaschke K, Wills S, Podojil JR, Popko B, Balabanov R, Miller SD. Interferon-? controls aquaporin-4-specific Th17 and B cells in neuromyelitis optica spectrum disorder. Brain. 2023 Nov 01. PMID: 37931066.
      Citations:    
    2. Perumal J, Balabanov R, Balcer L, Galetta S, Sun Z, Li H, Rutledge D, Avila RL, Fox RJ. Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis. Neurol Ther. 2023 Jun; 12(3):833-848. PMID: 36966440.
      Citations:    
    3. Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ. Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2023 Mar; 37(3):275-289. PMID: 36780107.
      Citations:    
    4. Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2022 09; 36(9):977-993. PMID: 36064841.
      Citations:    
    5. Titus HE, Xu H, Robinson AP, Patel PA, Chen Y, Fantini D, Eaton V, Karl M, Garrison ED, Rose IVL, Chiang MY, Podojil JR, Balabanov R, Liddelow SA, Miller RH, Popko B, Miller SD. Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis. Glia. 2022 10; 70(10):1950-1970. PMID: 35809238.
      Citations:    
    6. Loda E, Arellano G, Perez-Giraldo G, Miller SD, Balabanov R. Can Immune Tolerance Be Re-established in Neuromyelitis Optica? Front Neurol. 2021; 12:783304. PMID: 34987468.
      Citations:    
    7. Qian Y, Arellano G, Ifergan I, Lin J, Snowden C, Kim T, Thomas JJ, Law C, Guan T, Balabanov RD, Kaech SM, Miller SD, Choi J. ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Rep. 2021 08 24; 36(8):109602. PMID: 34433042.
      Citations:    
    8. Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ. Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 Jul; 38(7):3743-3744. PMID: 34159559.
      Citations:    
    9. Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742. PMID: 34014549.
      Citations:    
    10. Mondal S, Kundu M, Jana M, Roy A, Rangasamy SB, Modi KK, Wallace J, Albalawi YA, Balabanov R, Pahan K. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12R?1 internalization and suppress EAE. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21557-21567. PMID: 32817415.
      Citations:    
    11. Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019 10 29; 93(18):e1732-e1741. PMID: 31578302.
      Citations:    
    12. Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L. Outcomes of natalizumab treatment within 3?years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019 Jun 08; 19(1):116. PMID: 31176355.
      Citations:    
    13. Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931. PMID: 31139690.
      Citations:    
    14. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019 01 15; 321(2):165-174. PMID: 30644983.
      Citations:    
    15. Podojil JR, Chiang MY, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, Chen L, Vignali DAA, Miller SD. B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex. J Immunol. 2018 08 01; 201(3):897-907. PMID: 29898965.
      Citations:    
    16. Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, Lassmann H, Parisi JE, Pittock SJ, Stefoski D, Balabanov R, Lucchinetti CF. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014 Aug; 71(8):1025-9. PMID: 24911400.
      Citations:    
    17. Bienia B, Balabanov R. Immunotherapy of neuromyelitis optica. Autoimmune Dis. 2013; 2013:741490. PMID: 24455211.
      Citations:    
    18. Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11. PMID: 23008451.
      Citations:    
    19. Patel J, Balabanov R. Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2012; 13(8):10647-10659. PMID: 22949885.
      Citations:    
    20. Loda E, Balabanov R. Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination. Rev Neurosci. 2012 Jan 26; 23(2):145-52. PMID: 22499673.
      Citations:    
    21. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis. J Neurosci. 2011 Jun 08; 31(23):8329-41. PMID: 21653838.
      Citations:    
    22. Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59. PMID: 21257209.
      Citations:    
    23. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010 Jun; 5(2):260-5. PMID: 20177805.
      Citations:    
    24. Wang Y, Ren Z, Tao D, Tilwalli S, Goswami R, Balabanov R. STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. Glia. 2010 Jan 15; 58(2):195-208. PMID: 19606498.
      Citations:    
    25. Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21. PMID: 20064646.
      Citations:    
    26. Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD, Popko B. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci. 2007 Feb 21; 27(8):2013-24. PMID: 17314297.
      Citations:    
    27. Balabanov R, Strand K, Kemper A, Lee JY, Popko B. Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma. J Neurosci. 2006 May 10; 26(19):5143-52. PMID: 16687505.
      Citations:    
    28. Balabanov R, Popko B. Myelin repair: developmental myelination redux? Nat Neurosci. 2005 Mar; 8(3):262-4. PMID: 15746910.
      Citations:    
    Balabanov's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (140)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _